Risk stratification for proton pump inhibitor-associated type 2 diabetes: A population-based cohort study

Qiangsheng He, Man Yang, Xiwen Qin, Die Fan, Jinqiu Yuan, Yihang Pan

Research output: Contribution to journalLetterOtherpeer-review


We have recently reported in GUT that regular proton pump inhibitor (PPI) use was associated with a 24% increased risk of type 2 diabetes mellitus (T2DM).1 This was the first study demonstrating an association between PPIs and diabetes. However, all included participants were healthcare professionals and the findings have not been verified in general populations. Additionally, investigation of subgroups at high absolute risk of diabetes among PPI users is still lacking. Because the absolute effects of interventions tend to increase with baseline risk, individualised treatment based on the patients’ underlying risk may confer benefits and reduce harms. Such risk stratification strategy had been applied to select patients for antihypertensive and statin therapy.2 3 In the present study, we conducted a prospective analysis of the UK-Biobank to (1)confirm the association between PPI use and T2DM in general population and (2) to investigate which population groups may have high net risk.
Original languageEnglish
Article numbere323816
Number of pages2
Publication statusAccepted/In press - 2020


  • diabetes mellitus
  • proton pump inhibition

Cite this